ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical ...

Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company with a market capitalization of $209.5 million, today announced positive Phase 1 clinical trial results for its drug candidate ...

CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group with a market capitalization of $15.11 million, is ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned an average recommendation of “Buy” ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Zymeworks in a note issued to ...

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...

Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The ...

Cybin pushes forward with Phase 3 depression trials after posting a narrower loss, while securing a $100M funding program.

While 22 states have sued the Trump Administration to temporarily block a major policy change by the National Institute of ...

We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at ...